Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 131 to 140 of 220 total matches.
In Brief: Mechlorethamine Gel (Valchlor) for Cutaneous T-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
of a 60-g tube is $2900.2
SR Lessin et al. Topical chemotherapy in cutaneous T-cell lymphoma ...
The FDA has approved a 0.016% gel formulation of the nitrogen mustard mechlorethamine (Valchlor – Actelion) for second-line topical treatment of patients with stage IA or IB mycosis fungoides, the most common type of cutaneous T-cell lymphoma. Topical nitrogen mustard has been used off-label for decades for this indication, usually as a pharmacy-compounded ointment, but no clinical trials evaluating its efficacy and safety have been done. Mechlorethamine is also available in an injectable formulation (Mustargen – Recordati) for the same and other indications.FDA approval of Valchlor was...
In Brief: Trifluridine/Tipiracil (Lonsurf) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
in
800 patients with metastatic colorectal cancer who had
previously been treated with chemotherapy ...
The FDA has approved Lonsurf (Taiho Oncology), a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil, for oral treatment of metastatic colorectal cancer. Trifluridine is incorporated into DNA, interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil inhibits the metabolism of trifluridine. The combination is only approved for use in patients who were previously treated with a fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF biological such as bevacizumab, and, if the tumor...
In Brief: Two New Drugs for AML (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
chemotherapy- or radiation-related AML
or AML with myelodysplasia-related changes. Patients ...
The FDA has approved two new drugs for treatment of specific subtypes of acute myeloid leukemia (AML).Vyxeos (Jazz Pharmaceuticals) is a liposomal fixed-dose combination of daunorubicin and cytarabine, the standard drugs used for induction treatment of AML. It is approved for induction and consolidation treatment in adults with newly diagnosed chemotherapy- or radiation-related AML or AML with myelodysplasia-related changes. Patients with these subtypes of AML have a poor prognosis. The rationale for development of the combination was that nano-scale liposomal drug delivery vehicles prolong...
Ofatumumab (Arzerra) for CLL
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
, combination chemotherapy, or allotransplantation. Allotransplantation is most likely to be
successful when ...
The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal
antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine (Fludara, and others) and alemtuzumab (Campath). It is the second anti-CD20 antibody approved for treatment of CLL; rituximab (Rituxan), a chimeric murine/human antibody, was the first.
Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010 (Issue 1342)
TREATMENT — Initial treatment for
aggressive PTCL is usually a combination chemotherapy regimen ...
The FDA has approved pralatrexate (Folotyn – Allos), an intravenous (IV) antifolate, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the first drug approved by the FDA specifically for this indication.
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
with chemotherapy and/or hormone therapy is generally recommended for node-positive patients, and for node-negative ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Gleevec (STI-571) For Chronic Myeloid Leukemia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
been effective in treating
a rare, chemotherapy-resistant gastrointestinal stromal sarcoma (GIST). The drug ...
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
Oxaliplatin (Eloxatin) for Advanced Colon Cancer
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003 (Issue 1148)
• Vol. 45 (Issue 1148B) January 20, 2002 9
Chemotherapy Colorectal colorectal cancer fluorouracil ...
Oxaliplatin (Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil, and others) and leucovorin (LV; Wellcovorin) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan (Camptosar - Medical Letter 1997; 39:8).
Decitabine (Dacogen) for Myelodysplastic Syndromes
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006 (Issue 1247)
opportunistic infections due to immunodeficiency. Combination chemotherapy regimens, such as
cytarabine ...
Decitabine (Dacogen - MGI Pharma), a pyrimidine nucleoside analog of cytidine, was approved by the FDA as an orphan drug for treatment of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hemopathies that decrease production of normal blood elements (red cells, white cells and platelets) and are associated with a risk of progression to acute leukemia.
Glucose Control in the ICU
The Medical Letter on Drugs and Therapeutics • Jan 25, 2010 (Issue 1330)
) have both been FDA-approved
since 1985 for treatment of chemotherapy-induced
nausea and vomiting ...
Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients. Whether normalization of blood glucose by insulin infusion is beneficial in such patients has been a subject of debate in the critical care community. Some new guidelines have been published.
Click here to view the free full article.
Click here to view the free full article.